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A B S T R A C T
Dystrophin is a large intracellular protein that prevents sarcolemmal ruptures by providing a mechanical link
between the intracellular actin cytoskeleton and the transmembrane dystroglycan complex. Dystrophin dei-
ciency leads to the severe muscle wasting disease Duchenne Muscular Dystrophy and the milder allelic variant,
Becker Muscular Dystrophy (DMD and BMD). Previous work has shown that concomitant interaction of the actin
binding domain 2 (ABD2) comprising spectrin like repeats 11 to 15 (R11-15) of the central domain of dystro-
phin, with both actin and membrane lipids, can greatly increase membrane stifness. Based on a combination of
SAXS and SANS measurements, mass spectrometry analysis of cross-linked complexes and interactive low-re-
solution simulations, we explored in vitro the molecular properties of dystrophin that allow the formation of
ABD2-F-actin and ABD2-membrane model complexes. In dystrophin we identiied two subdomains interacting
with F-actin, one located in R11 and a neighbouring region in R12 and another one in R15, while a single lipid
binding domain was identiied at the C-terminal end of R12. Relative orientations of the dystrophin central
domain with F-actin and a membrane model were obtained from docking simulation under experimental con-
straints. SAXS-based models were then built for an extended central subdomain from R4 to R19, including ABD2.
Overall results are compatible with a potential F-actin/dystrophin/membrane lipids ternary complex. Our de-
scription of this selected part of the dystrophin associated complex bridging muscle cell membrane and cytos-
keleton opens the way to a better understanding of how cell muscle scafolding is maintained through this
essential protein.
1. Introduction
Dystrophin is a large intracellular protein that contributes to sup-
port membrane stretching or bending stresses developed during muscle
contraction and relaxation. It provides a mechanical link between the
intracellular actin cytoskeleton and the transmembrane dystroglycan
complex and thus helps prevent sarcolemmal ruptures (Campbell and
Kahl, 1989) mainly by behaving as a shock absorber (Ramaswamy
et al., 2011; Le et al., 2018). Dystrophin is a long ilamentous 427 kDa
protein made up of four main domains separated by hinges. In muscle
cells, the continuity between the internal ilamentous actin cytoske-
leton and the extracellular matrix is ensured by binding of dystrophin at
its N-terminus to actin ilaments through an actin-binding domain
(ABD1) and at its C-terminus, to β-dystroglycan. The latter protein
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spans the membrane and anchors the dystrophin glycoprotein complex
(DGC) with proteins of the extracellular matrix (Ervasti and Campbell,
1991; Ibraghimov-Beskrovnaya et al., 1992). While essential regions of
the dystrophin protein are located at both ends of the protein, the
central domain is also thought to play a key role in regulating the
membrane cytoskeleton and the extracellular matrix scafold. This
central domain of dystrophin comprises 24 spectrin-like repeats of ap-
proximately 100 residues each in which some specialized regions have
been shown to interact with numerous partners such as neuronal-nitric
oxide synthase (nNOS) (Lai et al., 2009), F-actin (Amann et al., 1998,
1999) and lipids (DeWolf et al., 1997; Legarnier et al., 2009). The
central domain was previously described as a “rod domain”. However,
in silico (Legrand et al., 2011) and in vitro (Delalande et al., 2018)
analyses showed that the central domain can no longer be considered as
a straight and passive linker between ABD1 and the C-terminus; rather,
its ilamentous structure is believed to have an important and dynamic
role in the scafolding of muscle cells through interactions with the
cytoskeleton (Amann et al., 1998; Sarkis et al., 2013) and membrane
lipids (Zhao et al., 2016).
Mutations in dystrophin are the cause of the severe muscle wasting
disease, Duchenne muscular dystrophy (DMD), a life-limiting, rapidly
progressive form of muscular dystrophy which is an X-linked recessive
disorder afecting 1:5000 boys (Stark, 2015) in which loss of dystrophin
destabilizes muscle membranes. Internal in-frame deletion mutations in
the dystrophin gene (DMD) that preserve the amino- and carboxyl-
termini of the protein but eliminate various parts of the central domain
cause the milder Becker muscular dystrophy (BMD) phenotype (Nicolas
et al., 2015). As observed in BMD patients, the dystrophin protein
therefore can tolerate internal deletions that maintain a shortened
central domain and the amino- and carboxyl-termini regions, this BMD
protein resulting in a more or less severe loss of muscle function. The
severity of the disease is not simply linked to the length of the protein
but much more to sophisticated and yet largely unknown functional
patterns of the shortened dystrophin (Nicolas et al., 2015; Wein et al.,
2015). Therapeutic strategies aim to convert DMD to the mildest BMD
possible by skipping or deleting out-of-frame exons and restoring the
expression of truncated forms of dystrophin protein (Yokota et al.,
2012). In parallel, due to the limited packaging capacity of viral vec-
tors, transport and expression of shortened forms of dystrophin, the so-
called mini- or microdystrophins, have been developed for gene therapy
(Belanto et al., 2014; Barthélémy and Wein, 2018). However, the pre-
cise consequences of in-frame deletions on the stability and function of
dystrophin are not to date predictable a priori, this is largely due to the
lack of knowledge on the molecular basis of dystrophin structure and
interactions. Given that current gene therapies for DMD aim to produce
shortened dystrophins, it appears essential to be able to predict their
properties compared with those of the native full length molecule. This
however remains dependent upon exhaustive knowledge of how wild
type dystrophin interacts in muscle cells. Particularly, a full under-
standing at the molecular level of the interaction of ABD2 with both F-
actin and membrane lipids is required. Thus, it appears crucial to
analyze the structure to function relationship of the full-length native
dystrophin.
Binding to F-actin is ensured through two subdomains of dystro-
phin. The irst one, located at the N-terminus, is named ABD1 and is
now well described as being composed of calponin homology domains
(Singh et al., 2012; Singh and Mallela, 2012; Winder et al., 1995a). It is
crucial in dystrophin since mutations of ABD1 that lead to a loss of F-
actin binding represent the second-most common cause of DMD
(Henderson et al., 2010). On the other hand, much less is known about
the second actin binding domain (ABD2) that is located in the central
domain. Early work from Ervasti’s group demonstrated that in the mdx
mouse, a rodent model of muscular dystrophy that lacks dystrophin, the
entire γ-actin network is poorly connected to the sarcolemma
(Sonnemann et al., 2006). This suggested a role for dystrophin in
maintaining the sub-sarcolemmal F-actin network in close register with
the membrane thus providing mechanical stability. Later experiments
demonstrated that a proteolytic product of dystrophin comprising
amino acids 1416–1880, from repeats 11 to 15 (R11-15) constituting
ABD2 (Lai et al., 2009; Sarkis et al., 2013) exhibited actin binding
properties, which could serve to reinforce the association of actin with
the membrane. These studies established a model that suggested dys-
trophin binds laterally along actin ilaments through the synergistic
efect of two distinct low ainity binding sites, which may hold im-
portant clues to its mechanical function in vivo (Henderson et al., 2012).
In addition it was shown that the dystrophin monomer is able to bind
along the length of one single actin ilament (Kumar et al., 1997;
Prochniewicz et al., 2009), the binding driven at least in part by elec-
trostatic interactions (Amann et al., 1998, 1999) and with a 1:3 to 5
ratio (Rybakova et al., 2006).
Previously, we investigated the lipid binding properties of the
spectrin-like repeats of the central domain and deined that repeats 1 to
19 would be able to bind membrane models in vitro (Vié et al., 2010,
Legarnier et al., 2009). Moreover we demonstrated that subdomain
R11-15 exhibits unique lipid-binding properties, namely the ability to
interact with anionic as well as zwitterionic lipids, and to adapt its
interaction and organization depending on lipid packing and lipid type
(Sarkis et al., 2011). From these studies, we suggested that the phy-
siological role of the central domain of dystrophin in sarcolemma
scafolding could partly occur through modulation of lipid-protein in-
teractions. Recent in vivo data are in line with our in vitro indings and
demonstrated that at least the R1-3 and R10-12 fragments are targeted
to the sarcolemma (Zhao et al., 2016).
Considering the above indings, we further hypothesized that both
sarcolemma and actin ilaments could bind simultaneously to dystro-
phin through the ABD2 subdomain, explaining the biological sig-
niicance of this region in vivo. By surface shear rheology measure-
ments, we showed that the central domain of dystrophin is able to
create a bridge between F-actin and membrane lipids, dramatically
modifying the membrane resistance to shear stress (Sarkis et al., 2013).
We concluded that ABD2 creates a mechanical link which likely con-
tributes in vivo to the protection of the sarcolemma from ruptures and to
the shock absorber function of dystrophin in muscle cells. Molecular
simulations of the dystrophin central domain (Legrand et al., 2011)
suggested that R11-15 is framed by lexible junctions and therefore can
be considered by itself as an independent subdomain of the dystrophin.
Resolution of Small-Angle X-ray Scattering (SAXS)-based models for
R11-15 (Molza et al., 2014, Delalande et al., 2018) and techniques like
small-angle neutron scattering (SANS) contrast-matching (Dos Santos
Morais et al., 2017), or crosslinking coupled with mass spectrometry
(XL-MS) applied to the study of dystrophin-bicelle complexes (Dos
Santos Morais et al., 2018) ofered us new opportunities to study central
domain structure and interactions at a molecular level. In the present
study, we investigated by a similar approach the interactions of dys-
trophin ABD2 with F-actin and with membrane lipids. We conclude that
both partners can together contribute to bridging cytoskeleton to sar-
colemma and propose a ternary model of the complex as a step forward
toward the ability to predict a priori the consequences of in-frame exon
skipping or the properties of microdystrophins for therapeutics.
2. Material and methods
Schematic representations of dystrophin and actin are shown on Fig.
S1A.
2.1. Dystrophin fragment production
All multi-repeat fragments were designed according to the align-
ment of Winder (Winder et al., 1995b).
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Name Recombinant protein se-
quence
MW
(kDa)
Number of resi-
dues
ε
(M−1.cm−1)
R1-3 GS EVNLD…QISQA 38.5 333 59,720
R11-15 GS FQKPA…LNFAQ 60.0 515 45,950
R8-15 (HIS6tev) RKEAL…LNFAQ 100.2 861 92,360
R11-19 (HIS6tevthb) FQKPA…
LLQEL
116.8 997 113,245
ABD1 GS LWWEE…IQEVE 29.1 253 51,575
Residues in italics are residual residues from a thrombin cleavage site.
Human dystrophin (Uniprot P11532).
2.2. DYS R1-3 cloning and expression in E. coli
The R1-3 fragment was produced and puriied as previously de-
scribed (Dos Santos Morais et al., 2018).
2.3. DYS R11-15 cloning and expression in E. coli
The DYS R11-15 (F1461-Q1973) fragment was ampliied by PCR from
pTG11025 plasmid DNA with the Dp427m human ORF (a gift from
Transgene SA, Strasbourg France) with primers designed including an
NdeI or XhoI restriction cassette (Integrated DNA Technologies) and
also including a 6xHis tag sequence followed by a thrombin recognition
site in the N-terminal region. PCR products were ampliied with Q5 HiFi
DNA polymerase (NEB), digested, puriied (Macherey-Nagel
NucleoSpin kit) and inserted into pET21 vector (Novagen) at the NdeI/
XhoI restriction sites. The His-tagged recombinant protein was pro-
duced in E. coli BL21(DE3) strain after 1mM IPTG induction for 4 h at
37 °C and puriied by immobilized metal ainity chromatography
(IMAC) on Ni-Sepharose column (HisTrap, GE Healthcare) according to
the manufacturer instructions. The His-tag was removed by thrombin
cleavage and the proteins were further puriied with a size-exclusion
chromatography column (HiLoad 16/600 Superdex 200 prep. grade, GE
Healthcare) equilibrated with TNE bufer (20mM Tris, 150mM NaCl,
and 0.1mM EDTA, pH 7.5). The purity was assessed by SDS-PAGE
stained with Coomassie blue. The concentration was determined spec-
trophotometrically using calculated molar extinction coeicients at
280 nm of 45,950M−1.cm−1.
2.4. DYS R8-15 and DYS R11-19 cloning and expression in insect cells
Extended (8 extra aa) R8-15 (R1148_Q1973) and R11-19 (F1461-L2420)
fragments were ampliied by PCR as described above. The R8-15 frag-
ment was inserted at the NcoI and XhoI sites with T4 DNA ligase (NEB)
into pFastBacHT vector (Invitrogen™). The R11-19 fragment was in-
serted at the BamHI and XhoI sites of a previously modiied pFastBacHT
including a thrombin recognition site in NcoI/BamHI. The constructs
were veriied by sequencing (Big Dye Terminator V3, Applera) and
transferred into DH10BAC cells (Invitrogen™) for recombination and
bacmid DNA production. Sf9 insect cells were transfected with 1 µg
bacmid DNA and Cellfectin-II reagent according to BAC-to-BAC in-
struction manual (Invitrogen™). Resulting baculoviruses were ampliied
for up to 3 passages.
Recombinant proteins were produced in Sf9 cells infected with ba-
culovirus for 3 days at 27 °C. Cells were lysed for one hour at room
temperature in phosphate bufered saline (sodium phosphate 25mM
pH8, NaCl 300mM) containing protease and phosphatase inhibitors
(Pierce), 50 µl/ml insect PopCulture reagent (Novagen), 10 U/ml
benzonase (Novagen) and 5mM imidazole. Lysates were clariied by
centrifugation at 15,000g, 30min, 4 °C; loaded onto a HisTrap excel™
Ni-NTA column (GE Healthcare, ÄKTA start instrument), washed with
PBS pH8+5mM imidazole. Puriied proteins were eluted in phosphate
bufer saline pH8 containing 50mM imidazole then subjected to gel
iltration onto a HiPrep 26/60 Sephacryl S-200HR column (GE
Healthcare, ÄKTA FPLC instrument).
2.5. Actin binding domain 1 (ABD1) cloning and expression
The ABD1 fragment was ampliied by PCR as described above, di-
gested by BglII/XhoI and cloned into the BamHI/XhoI restriction sites
of pGEX-4 T-1 vector (GE Healthcare). The protein was expressed in E.
coli strain ER2566 (NEB) and induced at an OD 600 nm of 0.5 with
1mM IPTG for 4 h at 37 °C. The puriication was performed according
to the manufacturer's instructions on a 5mL GSTrap FF ainity column
(GE Healthcare) with an Äkta start instrument and the protein was
eluted by an overnight cleavage at 4 °C with thrombin at 10 unit.mL−1
in 20mM Tris-HCl pH7.4, 150mM NaCl bufer.
2.6. Bicelle preparation
Bicelles were prepared as described previously (Dos Santos Morais
et al., 2017). The 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC),
1,2-dimyristoyl-sn-glycero-3-phospho-L-serine (DMPS), 1,2-dihexanoyl-
sn-glycero-3-phosphocholine (DHPC), 1,2-dimyristoyl-d54-sn-glycero-
3-phosphocholine-1,1,2,2-d4-N,N,N-trimethyl-d9 (DMPC-d67), 1,2-di-
myristoyl-d54-sn-glycero-3-[phospho-L-serine] (DMPS-d54), and 1,2-
dihexanoyl-d22-sn-glycero-3-phosphocholine-1,1,2,2-d4-N,N,N-tri-
methyl-d9 (DHPC-d35), conditioned in chloroform or chloroform/me-
thanol, were all purchased from Avanti Polar Lipids and used without
any further puriication. D2O, Tris-d11, and EDTA-d16 were from
Eurisotop. Chloroform or chloroform/methanol solutions containing
the appropriate amounts of either zwitterionic (DMPC/DHPC, 1:1) or
anionic (DMPC/DMPS/DHPC, 0.67:0:33:1) lipid mixtures were dried
overnight under vacuum. The lipids were then rehydrated in TNE or d-
TNE bufer solution (20mM Tris-d11, 150mM NaCl, and 0.1 mM
EDTA-d16, pD 7.5) to reach a total lipid concentration of at least
200mM. The solution was then frozen in liquid N2, thawed 10min at
40 °C, vigorously shaken for 1min, and centrifuged (1.5 min, 6000 rpm,
MiniSpin, Eppendorf). This procedure was repeated twice, to obtain a
clear suspension of zwitterionic or anionic bicelles in hydrogenated or
deuterated version, denoted HZB/DZB and HAB/DAB, respectively.
Stock solutions were diluted in TNE or d-TNE depending on the ex-
periments.
2.7. Intrinsic tryptophan (Trp) fluorescence
Fluorescence measurements (two replicates) were carried out on a
Fluorolog spectroluorometer (Jobin-Yvon). Tryptophan luorescence
emission spectra were recorded in low volume quartz Hellma cells
(120 µl) between 310 and 420 nm, using an excitation wavelength of
295 nm (bandwidth of 2 nm). Blanks corresponding to the bufer or
bicelles alone were subtracted from the respective spectra. The protein
concentration was 20 µM and the total lipid concentration was 50mM
(~150 μM of bicellar objects). The measurement temperature was
26 °C.
2.8. Circular dichroism
Quality control of all the puriied proteins was assessed by circular
dichroism with a JASCO J-815 (Nantes, France) spectropolarimeter
with protein concentration of about 1 µM. Spectra were acquired in the
range 200 – 250 nm at 20 °C with a path length of 0.2 cm. The per-
centage of α-helix was obtained using a 100% α-helix value of
−36,000 deg.cm2.dmol−1 at 222 nm and the ratio of the ellipticity at
222 over 208 nm was used as an indicator of the presence of a coiled-
coil as previously described (Legarnier et al., 2009). For R11-15-bicelle
interactions, two replicate spectra were recorded from 200 to 240 nm in
0.02-cm pathlength Hellma cells at 26 °C. Blanks corresponding to the
bufer or bicelles alone were subtracted from the respective spectra. The
protein concentration was 20 µM, and the total lipid concentration was
50mM (~150 µM of bicellar objects).
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2.9. Microscale thermophoresis (MST)
Bicelles were labeled with 1 µM of 1,2-dioleoyl-sn-glycero-3-
phospho-L-serine-N-(7-nitro-2–1,3-benzoxadiazol-4-yl) for a inal con-
centration of 15mM of lipids (~50 μM of bicellar objects) at qef=1.3
and the [DMPC]/[DMPS] (mol/mol) ratio into the bilayer part was
maintained equal to 2 (see Dos Santos Morais et al., 2018 for further
information). The bicelles were titrated with a 0.75-fold serial dilution
of R11-15 from 184 to 165 to 2.5–2.2 µM. The 16 solutions were then
loaded into Monolith NT premium capillaries (NanoTemper) and
thermophoresis was measured with a Monolith NT.115 instrument
(NanoTemper). Instrument parameters were as follows: 20–30% LED
power, 40–60% MST power, and 5/20/5 laser of/on/of. The mea-
surement temperature was 22 °C or 26 °C (two technical replicates).
Data were analyzed with the NT MO Ainity Analysis software v2.2.4
(NanoTemper).
2.10. Actin polymerization and sedimentation assays
Globular actin (G-actin) was prepared from rabbit muscle, as de-
scribed previously (Winder et al., 1995b). Cosedimentation assays were
performed as described in (Sarkis et al., 2013). Briely, monomeric G-
actin stored in G bufer (2mM Tris, pH 8.0, 0.2 mM ATP, 0.5 mM di-
thiothreitol, 0.2 mM CaCl2 and 1mM NaN3) was diluted in poly-
merization bufer (F bufer; inal composition: 20mM HEPES, pH 7.5,
150mM NaCl, 2 mM ATP, 50mM KCl, 2mM MgCl2, and 1mM dithio-
threitol) and allowed the polymerization at room temperature for 1 h.
Actin polymerization was assessed by light scattering at 400 nm. For
sedimentation assays, 50–100-µl samples were prepared in F-bufer in
ultracentrifuge tubes. The inal concentrations of actin were 5 µM and
0–150 µM for DYS R11-15. Following a 30min incubation, samples
were centrifuged for 30min at 100,000g at 20 °C. Supernatants and
pellets were analyzed by SDS-PAGE. Gels were stained with Coomassie
blue and the amounts of proteins quantiied by ImageJ software.
2.11. Click-chemistry, chemical cross-links and liquid chromatography
coupled with mass spectrometry (XL-LC-MS/MS)
2.11.1. R11-15 – F-actin
F-actin and R11-15 at 5 µM inal concentrations were incubated in
polymerisation bufer (without DTT) for 30min at 20 °C and then EDC
((1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride,
Thermoisher scientiic) was added at a concentration of 5mM for
60min at 20 °C. Cross-linked proteins were analyzed by SDS-PAGE
stained by Coomassie blue and the bands corresponding to one actin
monomer-one R11-15 monomer complexes were excised and cut into
small pieces.
2.11.2. R11-15 – bicelles
HZB and HAB were labeled with 5% (mol/mol) of 1-palmitoyl-2- (9-
(3-pent-4-ynyl-3-H-diazirin-3-yl)-nonanoyl)-sn-glycero-3-phosphocho-
line (pacFA PC) (Avanti Polar Lipids) bearing both photoactivable
diazirine and clickable alkyne groups on one tail of the phospholipid
(Haberkant and Holthuis, 2014). The modiied bicelles were mixed with
R11-15 to reach a inal concentration of 50mM of lipids and 15 µM of
protein. Then, the protein/lipid complexes were exposed to UVA ra-
diation (5×15W, Stratalinker, GE Healthcare) for 5min, just before
SDS-PAGE analysis. The staining was performed using Coomassie blue
(InstantBlue, Expedeon). The smeared parts of the gel, just above the
band corresponding to R11-15, were cut into small pieces.
2.11.3. Mass spectrometry sample preparation
For both lipid-R11-15 and actin-R11-15 complexes proteins con-
tained in the gel pieces were reduced, alkylated, and then digested with
trypsin (Promega). The resulting peptides were extracted as previously
described (Lavigne et al., 2012). The peptide extract was loaded (10 µl)
on a nano-HPLC system (LC Packings Ultimate 3000, Dionex) equipped
with a trapping precolumn (5mm×300 µm id, 300 Å pore size,
Pepmap C18, 5 µm, ThermoScientiic) and an analytical column
(15 cm×75 µm id, 300 Å pore size, Pepmap C18, 5 µm, Thermo-
Scientiic). Reversed-phase separation was performed with the same
gradient as described previously (Lavigne et al., 2012). Peptides were
directly eluted from the nano-HPLC column to the nanoelectrospray ion
source of a LTQ-Orbitrap XL (ThermoScientiic) mass spectrometer
operating in data-dependent mode by automatically switching between
full MS scan and MS/MS acquisitions on the 15 most intense precursor
ions as described previously (Jumeau et al., 2015). MS data were saved
in the RAW ile format with Xcalibur 2.0.7. For the lipid-R11-15 com-
plex, the RAW ile was subjected to a database search for protein
identiication using Mascot Distiller 2.6.1.0 and Mascot Server 2.5.1
with its automatic decoy database search. The database searched con-
tained the E. coli reference proteome from Uniprot (UP000000625,
April 2017), the contaminants database from Mascot and the sequence
of the R11-15 protein fragment (785 sequences, 14595443 residues).
Mass tolerance was set to 10 ppm for precursors and to 0.5 Da for
fragments. Trypsin was selected as enzyme with two missed cleavages
allowed. Protein modiications were: ixed carbamidomethylation of
cysteines and variable oxidation of methionine, and variable pacFA PC.
The pacFA PC modiication (C39H72NO8P, 713.4996 Da) was manually
deined in the Mascot coniguration editor with a neutral loss of
phosphocholine (C5H14NO4P, 183.066 Da). Since the photoactivation of
diazirine forms carbene intermediates that can react with any amino
acid side chain or peptide backbone, all amino acids were selected as
possible modiied sites. Proline Studio 1.4 was used for identiication
validation (peptide rank=1, false discovery rate < 1% at the peptide
spectrum match level) (Carapito et al., 2015). For the actin-R11-15
complex, the RAW ile was converted in the Mascot generic ile format
using Mascot Distiller and imported in the StavroX 3.6.6.5 (PMID:
22038510) software used to identify EDC cross-linked peptides. Cystein
carbamidomethylation was selected as static modiication whereas
methionine oxidation was selected as variable modiication. Precursor
and fragment tolerances were respectively set to 5 ppm and 0.5 Da. K
and R (both blocked by P) were deined as protease sites. Reported
results corresponded to a false discovery rate lower than 5% (Tables S1
and S2).
2.12. Small-angle scattering (SAS)
2.12.1. Small-angle X-ray scattering (SAXS) experiments
SAXS experiments were performed as described previously
(Delalande et al., 2018). Measurements were conducted at the French
synchrotron SOLEIL (Saint. Aubin, France) on the SWING beamline. All
experiments were performed at 15 °C. The scattering vector is deined
as q= 4pi/λ sinθ, where 2θ is the scattering angle. Data were collected
in a q-range of 0.006–0.6 Å−1. Data were recorded using an
AVIEX170170 CCD detector at the distance of 1.8m (λ=1.033 Å). For
the constructs R8-15 and R11-19, a stock solution of each fragment was
prepared at a inal concentration between 4 and 4.5mg/ml. A volume
of 60–70 μl of protein sample was injected into a size exclusion column
(Bio SEC-5 500 Ǻ, Agilent) and eluted directly into the SAXS low-
through capillary cell at a low rate of 0.2 or 0.3 mL/min. The elution
bufer consisted of NaPi 10mM pH 7.5, NaCl 500mM EDTA 1mM,
glycerol 2% or NaPi 20mM pH 7.5, NaCl 300mM, EDTA 1mM, gly-
cerol 2%. Two hundred ifty SAXS frames were collected continuously
during the elution at a frame duration of 1.5 s and a dead time between
frames of 0.5 s. One hundred frames accounting for bufer scattering
were collected before the void volume. The averaged bufer scattering
was then subtracted from the protein signal. SAXS curves displaying a
constant Rg in a Rg versus frame number plot were averaged and were
used for further characterization. Data reduction to absolute unit, frame
averaging, and subtraction were performed with FOXTROT. Data were
deposited in the SASBDB (Valentini et al., 2015).
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R8-15: https://www.sasbdb.org/data/SASDFW4/qlng5k8cq5/
R11-19: https://www.sasbdb.org/data/SASDFX4/eqrth3wghp/
2.12.2. SAXS data analysis
Analyses were performed as described in Delalande et al. (2018).
Briely, all data processing and analysis were conducted with the
Scatter software (http://www.bioisis.net/), and other programs of the
ATSAS suite (Franke et al., 2017). The distance distribution function P
(r) and the maximum particle diameter (DMAX) were calculated using
the GNOM program. The overall ab initio models of the protein frag-
ment R11-15 were obtained from the SAXS experimental data presented
in Delalande et al. Ab initio models for other fragments (R8-15 and R11-
19) where obtained using the GASBOR program, using 50 harmonics,
the scattering proiles were itted to a qmax=0.25 Å−1 for all samples.
Following a similar protocol to the one described previously, one
hundred independent GASBOR computations were performed for each
scattering proile, to factor the decrease in envelope convergence as-
sociated with the increased fragment size. For each fragment, the three
best GASBOR computations, with the smallest χ2, were conserved and
converted to volume grid constraints (molecular shape) to guide the
interactive lexible itting simulations, as described in previous work
(Molza et al., 2014). Before simulation, the homology model and the
molecular shape were aligned along their longest axis. The model was
then rotated 10 times around the long axis by 36° steps, followed by a
180° head-to-tail rotation to exchange N- and C-terminal end, before
performing 10 more rotations. The 60 models (3 envelopes, 10 rota-
tions, 2 directions) were adjusted afterwards. All inal models were
reined by standard energy minimization (Molza et al., 2014). The best
models were selected upon evaluation of the inal structural models
obtained using PROCHECK (Laskowski et al., 1993) and DSSP (Kabsch
and Sander, 1983; Touw et al., 2015) and by validation after calculating
their theoretical SAXS curves with the CRYSOL program (Franke et al.,
2017).
2.12.3. Small-angle neutron scattering (SANS) experiments
Preparatory work was carried out on KWS-1, KWS-2 (MLZ,
Garching), and PACE (LLB, Saclay), instruments, while inal investiga-
tions were done on D22 (ILL, Grenoble) instrument. Two to three
sample-to-detector distances were used with a wavelength varying from
4.7 to 7 Å (Δλ/λ~10%), to cover a Q-range from 0.008 to 0.5 Å−1 for
the largest one, where =Q sin4 is the momentum transfer, λ is the
wavelength, and 2θ is the scattering angle. All measurements were
performed in 1mm thickness Hellma QS cells, and the intensities ob-
tained are in absolute units (cm−1). Samples were analyzed in d-TNE
bufer at 22 °C. Exactly the same bufer that had been used for bicelle
rehydration was used to prepare protein/bicelle samples to guarantee a
perfect bufer subtraction. Bufer exchange for R11-15 was performed
by three successive diailtrations with Amicon Ultra-15 (Millipore,
MWCO 10 kDa), followed by a step with a desalting column (NAP5, GE
Healthcare). The protein concentration was 93 µM (5.6 g/l) and the
lipid concentration was 50mM. Data were deposited in the SASBDB
Valentini et al., 2015).
R11-15: https://www.sasbdb.org/data/SASDFT4/o4g9so8m49/
R11-15/DZB: https://www.sasbdb.org/data/SASDFU4/jvg81e6o1r/
R11-15/DAB: https://www.sasbdb.org/data/SASDFV4/rr58u3fhpg/
2.12.4. SANS data analysis
SANS data were analyzed similarly to SAXS data with the ATSAS
suite and Scatter software, following guidelines unless otherwise in-
dicated. Twenty ab initio models were generated with DAMMIF soft-
ware (https://www.embl-hamburg.de/biosaxs/atsas-online/) by con-
sidering the data up to Q=0.25 Å−1. The models obtained were
aligned and averaged with DAMAVER software. The presented ab initio
models correspond to the DAMMIF model with the smallest normalized
spatial discrepancy (NSD) surrounded by the corresponding DAMAVER
model.
2.13. Molecular simulation
2.13.1. Low-resolution docking
Rigid low-resolution docking was performed using Ptools software
(Schneider et al., 2012) to allow a large exploration of the association
modes of the dystrophin ABD2 with F-actin. Given the large size of the
12-mer F-actin model (3G37, Murakami et al., 2010) we deemed it
necessary to disallow edge efects upon docking the best 13 ABD2
models obtained previously from SAXS-driven lexible itting and se-
lected from energetic and structural criteria to allow a conformational
modulation of the ligand. The ABD2 models were reduced according to
the Zacharias force ield (Schneider et al., 2012). The dystrophin
starting position was deined using a density grid of 10 Å around the
four central G-actin monomers, corresponding to 80 starting positions
distributed as an open cylinder around the central F-actin part. For each
model, 20,640 theoretical complexes were inally calculated, corre-
sponding to 258 rotations applied to each starting position of the ligand
(ABD2) towards the receptor (F-actin). The rigid docking results were
analyzed through an energy evaluation of the theoretical complexes
and by clustering procedure using a root mean square deviation of 10 Å
according to the ligand inal position. The best theoretical complexes
are deined as the most populated clusters with the lowest ATTRACT
energy for the complex. The contact frequencies between the two
proteins were calculated over the 100 best clusters computed and with
a cut-of distance of 5 Å between two coarse-grain particles. Peptides
identiied by MS analysis of the cross-linked complexes were then used
to ilter theoretical complexes within the same distance constraints.
Interactive semi-lexible docking was performed by using BioSpring
software and following the protocol described previously (Molza et al.,
2014). Briely, due to the identiication of two distant interaction do-
mains, interactive docking was performed by ixing the actin ilament
and either R11 or R15 in contact to the actin and by interactively
bringing back the other end, unixed, toward the ilament, into a po-
sition identical to the ones identiied by Ptools docking. All starting
models for this interactive simulation were built through the substitu-
tion of the best positions obtained for either R11 or R15 contacts with F-
actin by the ABD2 model deposited in the SASBDB.
2.13.2. Coarse-grained molecular dynamics (CG-MD) simulations
CG-MD simulations were run using the GROMACS 5.0 program with
the Martini coarse-grained force ield. Two protein/lipid systems were
simulated in a similar way to what was done previously for the R1-3
dystrophin fragment with either zwitterionic bicelles or anionic bicelles
(Dos Santos Morais et al., 2018). The R11-15 (ABD2) SAXS-based model
used for the CG-MD is accessible through the online database SASBDB
at http://www.sasbdb.org/data/SASDB63/ (Delalande et al., 2018). All
CG-MDs were performed at a constant temperature of 303 K and under
NPT conditions for the production of inal CG-MD trajectories of 20 µs.
Analysis was achieved with the GROMACS 5.0 tools.
3. Results
3.1. Experimental data
3.1.1. Dystrophin ABD2 binds F-actin via repeats R11 and R15
Binding assays show that in our experimental conditions ABD2
binds F-actin with a Kd of ~9 µM with a Hill coeicient of ~ 1.9 (Fig.
S1B). Following incubation of F-actin with ABD2, the zero-distance
cross-linker EDC was added and the products were irst analyzed by
SDS-PAGE (Fig. 1). R1-3 and ABD1 (actin binding domain 1) fragments
of dystrophin were used as negative and positive controls respectively.
A speciic EDC induced band corresponding to the expected size of one
actin linked to one R11-15 is observed with an apparent MW of ~100 kDa
(Fig. 1A, red arrow). No non-speciic signal was observed in the absence of
EDC. When F-actin alone was incubated with EDC, a 130–140 kDa band
was identiied as an actin multimer (blue arrow in Fig. 1A and B and Fig.
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S1C). In the R1-3F-actin EDC mixture Fig. 1A lane 3), the actin polymer is
present at 130–140 kDa, a band at ~85 kDA was identiied as a R1-3
multimer and no cross-linked peptides from either proteins were identi-
ied. ABD1 used as a positive control is found speciically cross-linked to
actin in a ~70 kDa heterodimer (Fig. 1B red arrow). MS results are shown
in Tables S1 and Appendix Tables S1.
From the 100 kDa EDC induced band (Fig. 1A, red arrow), among
the trypsin proteolysis products identiied by MS, the peptides derived
from actin that are found cross-linked with peptides derived from ABD2
are shown in Table S1 and Fig. S1C. The two peptides from actin iso-
lated by MS with a high conidence are delimited by Ala21 and Arg30
or Val98 and Lys115. This means that the region of actin which is in
close contact with dystrophin ABD2 resides principally in subdomain 1
(Fig. S1A). Corresponding results deining the contact mapping on the
dystrophin ABD2 fragment characterize several peptides involved in the
interaction with F-actin. Interestingly all are included in repeats R11,
R12 or R15. These fragments are delimited by Phe1461 to Arg1470,
Ser1517 to Arg1527, Lys1533 to Lys1539 and Leu1550 to Lys1568 in
repeat R11, by Lys1645 to Lys1652 in repeat R12 and Lys1922 to
Arg1930 in repeat R15.
3.1.2. Lipid interaction with dystrophin slightly alters its structural
organization but does not overlap with F-actin contact regions
We characterized the ABD2-lipid interactions using bicelles as a
membrane mimic, in a similar approach to what we have done pre-
viously for R1-3 (Dos Santos Morais et al., 2018). First, the protein/
bicelle interactions were highlighted using Trp intrinsic luorescence
measurements, in the presence of either zwitterionic (HZB) or anionic
(HAB) bicelles. A small increase in luorescence was observed (Fig. S2A)
and conirmed the interaction. We then used circular dichroism (CD) to
probe potential structure modiications of dystrophin ABD2 during its
interaction with both types of bicelles (Fig. S2B). Our irst observation
is that the CD spectra of ABD2 alone is typical of a predominantly α-
helical structure with the presence of two minima at 222 and 208 nm,
suggesting that the recombinant protein is properly folded. Moreover,
the θ222/θ208 ratio is close to or above unity, which is evidence of an
overall coiled-coil tertiary structure (Vié et al., 2010). The CD spectra of
R11-15 alone or in the presence of both types of bicelles are very similar
suggesting that the secondary and tertiary structures of ABD2 are
maintained during binding to bicelles. Finally, we used microscale
thermophoresis (MST) to determine the dissociation constant (Kd) of
the complexes. A Kd value of ~10 µM was determined for the system
formed by ABD2 with both types of bicelles (Fig. S2C and D).
To investigate the potential 3D structural modiications of ABD2
upon lipid binding, we performed SANS experiments on ABD2 in the
presence of either zwitterionic (DZB) or anionic (DAB) contrast-mat-
ched deuterated bicelles (Dos Santos Morais et al., 2017) (Fig. 2A).
SANS measurements show that no change is observed in the case of
dystrophin ABD2 interaction with zwitterionic bicelles whereas the
interaction of dystrophin ABD2 does alter the fragment tertiary struc-
ture upon binding to anionic bicelles (increase of ~60 to ~80 Å of Rg
towards free fragment, conirmed by the increase of Dmax on P(r) plot in
Fig. 2A inset. The best ab initio models computed from the SANS ex-
periments for the dystrophin fragment in the presence of bicelles are
shown and demonstrate a very high degree of similarity of the protein
shape in solution by comparison to the models obtained from SAXS
experiments (Fig. S3). Finally, an accurate mapping of the interaction
between R11-15 fragment and both types of bicelles was investigated
by XL-MS. The protein–bicelle-pacFA complexes were submitted to UV
cross-link and analyzed by SDS-PAGE (Fig. 2B). If one or two pacFA
fatty acids covalently cross-linked to ABD2, the increase in apparent
MW would be only slight. Therefore, the smeared upper parts of the
bands corresponding to ABD2 with putatively associated lipid(s) were
cut from the gel and their trypsinolysis products were analyzed by MS.
No peptide-lipid cross-link was identiied in samples corresponding to
the zwitterionic bicelle protein complex. Interestingly however, one
peptide from ABD2 was identiied linked to the pacFA fatty acid in the
sample derived from the anionic bicelles. The score obtained for the
dystrophin ABD2 peptide bearing a pacFA modiication is presented in
Table S2 (see also Appendix for details), this peptide (1667AEE…
YQK1679) belongs to the C-terminal end of helix C in repeat R12 of the
dystrophin domain.
Fig. 1. (A) SDS-PAGE analysis of EDC induced F-actin-dystrophin central domain adducts. F-actin and R1-3 as a negative control, or R11-15 dystrophin fragments at
inal concentrations of 5 μM were incubated in the presence or absence of 5 mM of the EDC cross-linker for 1 h at 20 °C. Bands of interest were excised, trypsin
digested and analysed by MS. Blue arrow: 130–140 kDa band corresponding to EDC crosslinked multimer of actin. Red arrow: band corresponding to the expected
size of one monomer of R11-15 (ABD2) EDC-covalently cross-linked to one monomer of actin. (B) SDS-PAGE analysis of EDC induced F-actin-dystrophin ABD1 (actin
binding domain 1) displayed as a positive control. 5 µM of F-actin and ABD1 domain alone or together were incubated in the presence or absence of EDC. Samples
were centrifugated at 100.000 g. Pellets (P) and supernatants (S) were loaded on SDS-PAGE gels. Bound proteins sediment with F-actin in pellet. Bands of interest
were excised, trypsin digested and analysed by MS. Blue arrow: the Actin multimer as found in (A). Red-arrow: the speciic band corresponding to a monomer of
ABD1 EDC-covalently cross-linked to a monomer of actin.
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3.1.3. Dystrophin ABD2 interacts in vitro with both F-actin and membrane
lipids simultaneously
Ternary complexes comprising F-actin–dystrophin ABD2–bicelles
were studied in vitro. Only anionic bicelles were selected for these ex-
periments, due to the nature of the lipids found at the inner face of the
sarcolemma (Fiehn et al., 1971) and to our previous observations
(Legarnier et al., 2009; Sarkis et al., 2011). The EDC-cross-linked
ABD2/F-actin complex was irst achieved as described above, then
anionic bicelles containing the pacFA lipid were added and light-in-
duced cross-linking was performed. The result of SDS-PAGE analysis of
the samples is shown on Fig. 3A.
Four bands including R11-15 smear, CL1 (~100 kDa), CL2
(~130 kDa) and CL3 (~170 kDa) were analysed by MS. Results are
shown in Table S1 (complete version in Appendix). Actin and R11-15
cross-peptides were found in the CL1, CL2 and CL3 bands but not in the
smear band. Interestingly, the 100 kDa band, as observed from the
experiment presented in Fig. 1, was identiied as a cross-linked complex
between actin and R11-15. In this complex, the peptide from R11-15
(1667AEEWLNLLLEYQK1679) is found linked to the pacFA. All indings
are summarized in Fig. 3B. In the R11-15 (ABD2) model, the peptides
associated with actin peptides are highlighted in orange. All are located
exclusively in repeats R11, R12 and R15. The peptide from helix C in
repeat 12 of ABD2 was, as earlier observed in a binary ABD2-bicelle
complex, found associated with lipids (highlighted in green).
Actin binding peptides are located exclusively in repeats R11, R12
and R15 and the lipid binding peptide is located in repeat R12. More
precisely, actin and lipids bind clearly on opposite extremities of helix C
in repeat 12. While all the cross-link experiments were achieved with F-
actin ilaments, for clarity, we report on a monomer model of actin the
peptides bound to ABD2 (Fig. 3C). This model shows that the areas of G-
actin bound to ABD2 do not correspond to monomer–monomer inter-
actions but to solvent accessible domains on a double-stranded actin
ilament. All together these results strongly suggest that dystrophin
ABD2 can interact together with F-actin and membrane lipids.
3.2. Molecular modeling data
3.2.1. Dystrophin ABD2 in solution is a well-structured subdomain
We sought to propose a structural model of the dystrophin ABD2
bound to F-actin in accordance to the experimental mapping obtained
here. Therefore, we irst needed to improve the analysis of SAXS data
previously acquired before the launch of molecular docking computa-
tions (Fig. S3A and B and see Supporting Information). Over the 60
geometries optimized under SAXS restraints, we observe that the four
best new models for ABD2 converge remarkably (Fig. S3C) including
major kinks between R12 and R13 and between R14 and R15. The
improved method used here therefore allows us to conirm the main
topographical organization emerging from the ab initio treatment of
SAXS data, ie the location of major kinks in the ABD2 subdomain. We
also noticed that the acute R14-R15 kink is remarkably well conserved
with an angle close to 81 ± 6° between main axis of the two R14 and
R15 coiled-coils. However, the relative position of the R11-12 tandem
towards the rest of the fragment difers slightly from one model to
another due to possible changes in the R12-13 linker organization.
Surface properties of the ABD2 fragment illustrate the ambivalent be-
havior of this subdomain well, in that it is highly stable in aqueous
bufer but is also able to bind lipids in vitro (Fig. S3D and E).
3.2.2. Electrostatics drive the preferential binding of the ABD2 model to F-
actin through repeats R11 and R15
Rigid low-resolution docking simulations were achieved by using
previously selected R11-15 SAXS-based models as ligand, and with F-
actin structure as receptor (Fig. S4). As a irst step, we computed more
than 20,000 theoretical complexes per ABD2 conformer with an almost
exhaustive approach and without any restraints from the contact
mapping obtained experimentally. After projection of all docking con-
tacts on a single G-actin for a cumulative analysis of the contact fre-
quencies of dystrophin onto the F-actin (Fig. S4A), it appears that
dystrophin ABD2 does interact in a preferential manner with sub-
domains 1 and 3 of a given G-actin unit (Fig. S4B). The highest contact
frequencies that were observed for the dystrophin ADB2 interacting
with F-actin essentially concern repeats R11 and R15, the two most
zwitterionic repeats of ABD2 (Fig. S3E and D). These observations are
in good agreement with the experimental mapping obtained from XL-
MS analysis (Fig. 3B). In a second analysis step of the calculations, the
contact frequencies were iltered by only keeping the theoretical com-
plexes that were in accordance with the ABD2–F-actin mapping ex-
periments (Fig. 4A, Fig. S4C and E).
Fig. 2. (A) SANS scattering curves of dystrophin R11-15 fragment either free (green) or in interaction with zwitterionic bicelles (DZB) (blue) or anionic bicelles (DAB)
(red). Inset: (left) Pair-distribution function P(r) analysis with the same color code showing a slight increase of Dmax of R11–15 when the protein fragment is in
interaction with anionic bicelles and (right) ab initio models corresponding to the DAMMIF associated models (colored) with the smallest normalized spatial
discrepancy (NSD) are shown, surrounded by their relative DAMAVER models (grey). (B) SDS-PAGE analysis of R1-3 and R11-15, alone or following incubation with
zwitterionic-pacFA or anionic-pacFA bicelles and light-induced cross-links. The upper part of the band containing putative protein-lipid covalent complexes were cut
into small pieces and analyzed by MS (red arrows).
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Finally, it conirmed that ABD2 contacts F-actin at a site far from the
interface deined by the contact region of subdomains 3 and 4 of dif-
ferent actin subunits, when associated in a ilament. Following the
standard analysis proposed by Attract and based on an internal energy
ranking and geometrical clustering of ligand poses, the best ABD2–F-
actin theoretical complexes were selected (Fig. 4B). In these models,
repeat R11 of ABD2 binds preferentially in a manner that enables the
orientation of the dystrophin ilament in the same direction as the main
axis of F-actin, forcing a small contact site at repeat R12 due to its
proximity. Nevertheless, it also clearly shows the disengagement of the
main part of repeat R12 from close contact with the actin ilament
thanks to a moderate kink at the R11-R12 linker. On the contrary,
Fig. 3. (A) SDS-PAGE analysis of the F-actin-R11-15-pacFA ternary complexes. R11-15 and F-actin were submitted to EDC cross-link. Then the products were
incubated in the presence of anionic bicelles containing pacFA (HAB-pacFA) before light activated cross-linking; Coomassie blue staining. CL1 Arrow: ~100 kDa band
corresponding to one monomer of R11-15 cross-linked to one monomer of actin (as in Fig. 2B) and putatively associated with the pacFA lipid (additional MW of 1 kDa
not detectable by SDS-PAGE). Additional CL2 and CL3 bands corresponding to cross-linked multimers. R11-15 smear, CL1, CL2 and CL3 were excised and analyzed
by mass spectrometry. (B) Peptides experimentally identiied to contact F-actin (orange) and anionic bicelle (green) mapped on the backbone of the dystrophin ABD2
fragment (grey); (C) 3D model of G-actin (PDB 3G37) showing the actin monomer standard subdomains; right: Peptides from actin experimentally identiied to
contact ABD2 (blue) mapped on the backbone of a single G-actin unit (grey).
Fig. 4. (A) Contact frequencies of the
dystrophin ABD2 with the F-actin
structure all over the docking simula-
tions: raw data obtained by rigid low-
resolution docking (left) and same data
after iltering of the sole solutions in
accordance to experimental mapping
(right). (B) Best (Attract energy and
cluster size) theoretical complexes
computed for the association of dystro-
phin (purple and blue) ABD2 to the F-
actin (yellow and orange) show two
main independent groups of solutions
verify experimental mapping. The irst
cluster shows a great accordance con-
cerning the experimental interaction
with repeat R11 and F-actin (left), as
the other one shows a great accordance
concerning the experimental interac-
tion between repeat R15 and F-actin
(right).
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repeat R15 contacting models highlight that the acute kink character-
ized at the R14-15 linker (Delalande et al., 2018) could play an essential
role in accommodating the two F-actin and dystrophin ilaments. It
appeared at this stage that none of these models could verify a double
contact from both repeats R11 and R15 in the same complex (Fig. 4B),
as we can hypothetize from co-sedimentation assay analysis and Kd
measurements found in the literature (Amann et al., 1998, 1999;
Rybakova et al., 2002). Nevertheless, these docking simulations pro-
vided high quality orientations for each isolated R11/R12 and R15
repeats towards F-actin. They were then further used as starting
structures for inal improvements incorporating ABD2 lexibility.
3.2.3. The ABD2 model could contact two different strands of the F-actin
microfilament
Interactive lexible docking is a technique to improve docking
models as we already discussed earlier (Molza et al., 2014). Through
interactive simulations, we explored the multiple possibilities in the
positioning of repeats R11 and R15 relative to each other, both in terms
of distance (number of actin units separating each contacting monomer
from+1 to+6) and topology (same strand of microilament or not).
To achieve this, we ixed either the position of repeat R11 or of repeat
R15 according to the best models obtained from rigid docking (prin-
ciple shown in Fig. 5A).
All the best models computed by this approach derived from the
same type of simulations, namely the one in which repeat R11 was
restrained and the rest of the dystrophin ABD2 was driven to investigate
the contacts experimentally mapped on repeat R15 (Fig. 5A and 5B). By
closely characterizing the main properties of the molecular surfaces
involved in the interaction between ABD2 and F-actin, we conclude that
electrostatics should play a key role in the association (Fig. 5C). How-
ever, the edge of the actin ilament accommodating repeat R15 of
dystrophin could also be crucial for the stabilization of the complex
through speciic hydrophobic patches (Fig. 5D). Finally, after compar-
ison of contact analysis of our best models with the experimental
mapping, we can conclude that repeats R11 and R15 in ABD2 are
ideally located on opposite strands of F-actin (Fig. S4F). Simulations
bearing the best evaluation criteria (see Material and Methods) show a
contact analysis with repeats R11 and R15 separated by+ 5 actin
subunits along the F-actin ilament. Interestingly, co-sedimentation
assays have a stoichiometry of 1 to 3, suggesting that a single R11-15
fragment binds twice to an actin ilament every 6 actin monomers.
However, the simulation results associated with a contact every 3, 4 or
6 actin subunits would lead to structural features not compatible with
experimental data. For the+ 3/+4 actin monomers hypothesis, this
would imply a thermodynamically unfavorable bending of the dystro-
phin ilament. For the+ 4/+6 actin monomers hypothesis, this would
result in continuous contact with actin all along the dystrophin frag-
ment (Fig. S4F), which would be incompatible with MS data and with
the lipid interaction map (see later). Consequently, these results suggest
that the dystrophin ilament should follow the F-actin helicity through a
double contact with two opposite strands of the same microilament.
3.2.4. Dystrophin binds to both anionic and zwitterionic bicelles at their
outer toroidal surface
Low-resolution molecular dynamics (CG-MD) simulations have been
used to explore molecular mechanisms that could lead to ABD2-bicelle
interactions, and considering zwitterionic bicelles as a control. First,
during CG-MD simulations, the dystrophin ABD2 is slowly recruited by
zwitterionic bicelles whereas it is quickly and spontaneously bound to
anionic bicelles (Fig. S5A and B). But more interestingly, we observe a
very diferent relative position of the dystrophin ABD2 fragment to-
wards each bicelle type (Fig. S5C and D). Both interact with the tore
part of the disk, a region with an increase in packing defects and is thus
more hydrophobic. ABD2 at this stage is only contacting zwitterionic
bicelles through repeat R15 whereas R11 to R13 repeats lie all along the
anionic bicelle side. It is noteworthy, that the peptide identiied by XL-
MS for the R11-15/HAB complex was found in repeat R12, in agree-
ment with the CG model obtained. The diferent features observed in
MD simulations can be related to the moderate conformational changes
of dystrophin ABD2 observed by SANS, as the more expanded contact of
ABD2 with anionic bicelles could diminish the kinks observed in solu-
tion at the linkers and therefore result in a more elongated structure.
3.2.5. Dystrophin R4-19 model is compatible with a simultaneous
accommodation of the ABD2 interactions with F-actin and sarcolemmal
lipids
In contrast to dystrophin ABD1 which is a subdomain separated by
hinge H1 from the central domain, (see Fig. S1A) ABD2 belongs topo-
logically to a long R4-19 fragment delimited by hinges H2 and H3. Our
previous structural study of the central domain highlighted kinks at
Fig. 5. (A) Principle of the lexible docking. In this example, the dystrophin repeat R11 is ixed on the actin ilament following the best pose obtained by the previous
docking step. During the interactive simulation, the rest of the ABD2 fragment is driven to it the experimental contact obtained for the dystrophin repeat R15. The
two R11 and R15 repeats of ABD2 contacting the F-actin could be spaced from +1 to +6 actin monomer from each others but with diferent efects on the structure
stability of the dystrophin. (B) Structure of the best model for the complex formed by the dystrophin ABD2 (yellow cartoon) and F-actin (grey volume) and verifying
both contacts of the dystrophin repeats R11 and R15 with the actin ilament. Peptides identiied by experimental mapping are shown as a blue volume for F-actin and
as an orange volume for dystrophin. (C) and (D) electrostatic and hydrophobic molecular potentials for the characterization of the interacting surfaces between both
proteins; (C) Electrostatic potential is set for isovalues of± 50kTe (blue for positive and red for negative, from APBS calculations); (D) Molecular Hydrophobic
Potential (MHP from Platinum calculations, see Pyrkov et al., 2009) with normalized values ranging from −1 (green, hydrophillic) to +1 (yellow, hydrophobic).
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speciic linkers. However some missing features remained for the R10
repeat – and consequently for R9-10 and R10-R11 linkers – and for the
R15-16 mini-hinge. As the study of ABD2 interactions with partners
could sufer from these missing structural data, we produced R8-15 and
R11-19 dystrophin fragments and analyzed them by using the small-
angle X-ray scattering approach combined with interactive lexible
itting techniques (Molza et al., 2014). Both fragments were expressed
in insect cells, and purity was assessed by SDS-PAGE (Fig. S6A). CD
spectra show that both proteins exhibit a typical mainly coiled-coil
structure (Fig. S6B) and SAXS curves typical of non aggregated proteins
with elongated shapes were obtained (Fig. S6C). Global parameters
measured indicate that the radius of gyration were 100 Å for R8-15 and
90 Å for R11-19 (Fig. S6D). Thus the dystrophin R11-19 fragment is less
elongated in solution than the R8-15 fragment, despite the presence of
one additional repeat. This feature is well illustrated by the best ab initio
models generated for each of the fragments (Fig. S6D and F). High
quality χ2 values of their related theoretical SAXS curves (2.5 to 2.6 for
R8-15 and 0.8 to 0.9 for R11-19) and the great convergence of their ab
initio models (NSD < 3.4 Å for R8-15 and NSD < 3.8 Å for R11-19)
support the relevance of using these models as a volume guide for
lexible itting. The SAXS-based atomic models obtained for these two
new central domain fragments (SASDFW4 and SASDFX4 in the
SASBDB), were inally used to produce an extended three-component
complex with F-actin, dystrophin R4-19 and a membrane model. By
maximizing the overlapping regions of the newly characterized frag-
ments (R8-15 and R11-19) and the fragments previously modelled (R4-
9, R11-15 and R16-19) (Delalande et al., 2018), we proposed a R4-19
subdomain model in good agreement with the kinks previously deined
at the linker regions (Fig. S7A and B). Positioning of the complete R4-19
SAXS-based model according to the theoretical model of ABD2–F-actin
was achieved without structural outliers (Fig. 6).
4. Discussion
4.1. Dystrophin ABD2 is defined by two interaction subdomains localized in
repeat R11 and repeat R15
Until now, the boundaries of the dystrophin second actin binding
domain were still under debate as authors irstly proposed an inter-
acting region ranging from repeat R11 to repeat R17 (Rybakova et al.,
1996; Amann et al., 1998), whereas later studies showed that R11-15
was suicient for the binding of the dystrophin central domain to F-
actin (Sarkis et al., 2013). Due to protein fragment expression and
stability, we chose to limit the ABD2 region to R11-15 and conirmed
the presence of contact patches involving a large part of repeat R11
(and a small neighbouring site in R12) and a short region within repeat
R15. On the actin side, we described for the irst time subdomains 1 and
3 to be the main regions interacting with the dystrophin central
domain. These results seem to be coherent with the molecular surface
potentials computed from structure and models of both protein part-
ners. Indeed, F-actin is electrostatically highly negative and as pre-
dicted from our systematic potential analysis proposed earlier, so are
the dystrophin repeats (Legrand et al., 2011). It is notable however, that
R11 and R15 are the two most zwitterionic repeats of the R11-15
dystrophin fragment. This could facilitate an association between both
ilaments even through a mechanism mainly based on electrostatics as
suggested earlier (Amann et al., 1998). In addition, the experimental
mapping procedure naturally provides peptides from both partners
linked in most of the cases by salt-bridge interactions in the native
complex, as the EDC chemical cross-linker is bridging acidic and basic
residues. This might artiicially emphasize the importance of electro-
statics in our case, given also that hydrophobic regions could play a
signiicant role in the association of the dystrophin ilament with F-
actin, as they comprise the core of the binding sites. Finally, we propose
that dystrophin would use repeats R11/R12 and R15 to contact two
diferent strands of the actin ilament with a distance of+ 5 actin
subunits between them, in accordance to a two binding site model itted
to binding assays. Measurement of average distances in the models
between R11 and R15 repeats and between two actin subunits distant
from+5 (~170 Å and ~140 Å, respectively) seem to strengthen this
hypothesis as other positions computed for dystrophin towards F-actin
have shown to be unrealistic in terms of topological organization. It is
also noticeable that stoichiometry assays we performed (1:3 for
ABD2:G-actin) strongly support these results if we consider that dys-
trophin can fully decorate F-actin. Nevertheless, speciic cross-linking
of a single ABD2 simultaneously on two actin monomers could have not
been observed through MS mapping, probably due to the relative rarity
of EDC crosslinking event.
4.2. Dystrophin actin-binding domain 2 allows structurally non-overlapping
interaction with F-actin and phospholipids
As the two main binding interfaces of ABD2 are located on the
widely spaced repeats R11 and R15, it can be deined as a non-con-
tinuous subdomain of the dystrophin central domain. This is compatible
with the location of the lipid binding site of ABD2. Indeed, we accu-
rately characterized dystrophin repeat R12 as the major binding region
with anionic bicellar systems. This result is also consistent with the
results obtained by Zhao et al. that showed the R10-12 dystrophin
fragment to be a lipid-binding domain in vivo (Zhao et al., 2016). In
previous work, our in vitro studies correlated well with in vivo studies by
the same authors, all together leading to the conclusions that the R1
repeat of dystrophin central domain exhibits membrane lipids binding
properties. For the ABD2 interaction with lipids, it is noticeable that
from our MD simulations, dystrophin ABD2 preferentially binds to the
outer toroidal surface of the bicelle, a region exhibiting packing defects
Fig. 6. Final structural model of the DYS R4-19
subdomain (white molecular surface) bound to F-
actin (orange) and sarcolemma (violet) through
contact peptides identiied by cross-link chemistry
and mass spectrometry. Repeats R11 and R15 are in
contact with F-actin while R12 may be simulta-
neously in contact with membrane lipids (purple).
Extension to N-terminal and C-terminal ends of
ABD2 allow to observe the disengagement of dys-
trophin central domain from the F-actin binding
area (red arrows), and this should result in the re-
duction of steric hindrance in the case of interaction
with other cellular partners.
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(Dos Santos Morais et al., 2018). This observation highlights that the
interaction of dystrophin with phospholipids would be mainly stabi-
lized by hydrophobic interactions. This hypothesis is also supported by
experimental mapping results as the location of the clickable chemical
group on the UV-photoactivable lipids is at the very end of their ali-
phatic chain. Indeed, the pacFA is a long-chain phospholipid that
should be buried in the bilayer part of the bicelle and the end of its
aliphatic chain carrying the clickable chemical group should only be
accessible to a protein on the outer toroidal surface of the bicelle thanks
to packing defects. However, the speciic behavior of dystrophin to-
wards anionic bicelles but not towards zwitterionic bicelles indicate
that electrostatics or hydrogen bonding could also play a minor role in
the recruitment or in the stabilization of dystrophin-sarcolemmal in-
teractions.
One major conclusion from our work is that the lipid binding region
does not overlap with the actin binding regions suggesting a possible
simultaneous interaction with these two components. This result is
consistent with our previous work based on the trypsin proteolysis
assay of ABD2 bound to lipid vesicles (Sarkis et al., 2011). The in-
tegrative structural model that we propose is in keeping with the ex-
perimental restraints related to the structure of the dystrophin central
domain (DYS R4-19) and the ABD2 interaction patterns with F-actin
and lipids. The binding of ABD2 to F-actin as measured by co-sedi-
mentation assays has a Kd of ~9 µM, in accordance with what was
reported previously (Amann et al., 1998). Interestingly by microscale
thermophoresis, we measured a similar Kd of ~10 µM for the interac-
tion of the same ABD2 fragment with both kinds of bicelles. These
observations could be of a great importance if veriied in a cellular
context.
4.3. Dystrophin actin-binding domain 2 as a structural relay for dystrophin-
actin-lipid complex
The location of the R11-15 lipid and actin binding domain, right on
the middle of the dystrophin central domain suggests it could act as a
tether, keeping the dystrophin close to the membrane and to the sub-
sarcolemmal cytoskeleton. This function would be otherwise only
achieved by the widely distant ABD1 (at the N-terminal end) and beta-
dystroglycan anchoring (at the C-terminal end) (Chen et al., 2003). This
is supported by the fact that currently designed micro-dystrophins that
restore part of the muscle resistance to mechanical stress in animal
models (Ramos et al., 2019) exhibit large internal deletions in the
central domain. In all cases ABD2 is missing in these therapeutic pro-
teins. In addition, very mild forms of BMD are observed in patients
lacking large parts of the central domain including ABD2 (Nicolas et al.,
2015). Dystrophin ABD2, apparently dispensable in shorter proteins,
could help to keep the dystrophin ilament correctly localized all along
length of the native protein. However, given that the central domain is
believed to act as an interaction hub, a large deletion in it could lead to
some loss of partners (like nNOS or syntrophin, Molza et al., 2015). One
hypothesis is that, when the full length protein is present in healthy
people, a spatial intermediary scafolding function including a bridge
between membrane and cytoskeleton actin would be necessary. This
seems largely counteracted by the beneit of bringing the N-terminal
end closer to the C-terminals end, eliminating the need for a central
tether. In conclusion, the physiological role of ABD2 remains to be fully
established. It appears to be dispensable in some mild BMD or in
therapeutic micro and minidystrophins. An intermediary scafolding
role would be necessary for the full length protein but unnecessary
when the protein is very short.
One however has to keep in mind that severe BMDs may be ob-
served with either ABD2 being present or not, as many other structure
to function features in dystrophin are involved and to date not fully
understood. For all gene therapy strategies in progress (Duan, 2018) for
muscular dystrophies that aim to express shortened dystrophins, fun-
damental knowledge of structure to function relationship of the protein
is required.
5. Short conclusion section
Most gene therapy strategies for muscular dystrophies aim to ex-
press shortened dystrophins. Fundamental knowledge of structure–-
function relationships of the protein is required. In this paper we show
that the interaction of actin binding domain 2 in the central domain of
dystrophin with ilamentous actin is achieved through selected areas in
spectrin-like repeats 11 and 15. On the other hand, lipids are found to
interact only with repeat 12 in ABD2. The lipid binding region does not
overlap with the actin binding regions. This suggests a simultaneous
interaction of ABD2 with these two components. Both partners can
contribute together to tether the cytoskeleton to the sarcolemma. We
propose a ternary model of the complex in agreement with experi-
mental constraints. This represents a step forward toward the ability to
predict a priori the consequences of in-frame exon skipping or the
properties of microdystrophins for therapeutics.
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